Merus N.V. Employee Directory
Biotechnology ResearchUtrecht, Netherlands201-500 Employees
Merus N.V. is a biotechnology research company focused on developing cancer therapeutics, with its most advanced programs built around Biclonics, a bispecific antibody approach designed to engage the immune system while directly inhibiting tumor growth and survival pathways. The company aims to provide multi-pronged anti-cancer therapies and has several candidates in clinical trials. It is headquartered in Utrecht, Netherlands, with offices in the United States and collaborations around the world, and it has been listed on NASDAQ since 2016. Within oncology, Merus collaborates with other organizations to advance its therapies and diagnostic strategies. A notable recent development is an exclusive license agreement announced in December 2024 with Partner Therapeutics for the commercialization of zenocutuzumab (Zeno) for NRG1+ cancers.